Advertisement
PDSB vs PRAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDSB is a Hold and PRAX is a Buy.
PDSB's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 70 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PRAX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PRAX turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 42 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRAX as a result. In 85 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRAX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 257 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 181 of 203 cases where PRAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.498). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PDSB | PRAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 34 | 38 | |
P/E GROWTH RATING 1..100 | 96 | 32 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PDSB's Valuation (6) in the Pharmaceuticals Major industry is in the same range as PRAX (19) in the null industry. This means that PDSB’s stock grew similarly to PRAX’s over the last 12 months.
PRAX's Profit vs Risk Rating (86) in the null industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to PDSB’s over the last 12 months.
PRAX's SMR Rating (97) in the null industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to PDSB’s over the last 12 months.
PDSB's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as PRAX (38) in the null industry. This means that PDSB’s stock grew similarly to PRAX’s over the last 12 months.
PRAX's P/E Growth Rating (32) in the null industry is somewhat better than the same rating for PDSB (96) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew somewhat faster than PDSB’s over the last 12 months.
| PDSB | PRAX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Advances ODDS (%) | 14 days ago 82% | 1 day ago 85% |
| Declines ODDS (%) | 1 day ago 90% | 10 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PDSB’s FA Score shows that 1 FA rating(s) are green while PRAX’s FA Score has 2 green FA rating(s).
- PDSB’s FA Score: 1 green, 4 red.
- PRAX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PDSB’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s).
- PDSB’s TA Score: 4 bullish, 5 bearish.
- PRAX’s TA Score: 4 bullish, 6 bearish.
Price Growth
PDSB (@Biotechnology) experienced а -26.95% price change this week, while PRAX (@Biotechnology) price change was +20.35% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
PDSB is expected to report earnings on Nov 12, 2026.
PRAX is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PDSB and
Correlation & Price change
A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To PDSB | 1D Price Change % | ||
|---|---|---|---|---|
| PDSB | 100% | -0.97% | ||
| AXON - PDSB | 43% Loosely correlated | +4.26% | ||
| PRAX - PDSB | 35% Loosely correlated | +2.55% | ||
| VCYT - PDSB | 35% Loosely correlated | +4.36% | ||
| ARRY - PDSB | 35% Loosely correlated | +9.94% | ||
| ATNM - PDSB | 34% Loosely correlated | +1.27% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with FULC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | +2.55% | ||
| FULC - PRAX | 45% Loosely correlated | +0.54% | ||
| IMVT - PRAX | 44% Loosely correlated | +3.72% | ||
| LXEO - PRAX | 43% Loosely correlated | +0.33% | ||
| CGEM - PRAX | 42% Loosely correlated | +1.07% | ||
| CELC - PRAX | 42% Loosely correlated | -4.07% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LCLG | 69.42 | 1.15 | +1.69% |
| Logan Capital Large Cap Growth ETF (LCLG) | |||
| QVML | 45.21 | 0.47 | +1.06% |
| Invesco S&P 500 QVM Multi-factor ETF (QVML) | |||
| EFR | 10.27 | 0.02 | +0.20% |
| Eaton Vance Senior Floating-Rate Fund | |||
| NRSH | 26.82 | N/A | N/A |
| Aztlan North America Nearshoring Stock Selection ETF (NRSH) | |||
| SIJ | 18.02 | -0.47 | -2.52% |
| ProShares UltraShort Industrials (SIJ) | |||